These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
914 related articles for article (PubMed ID: 33772767)
21. Evidence for increased SARS-CoV-2 susceptibility and COVID-19 severity related to pre-existing immunity to seasonal coronaviruses. Wratil PR; Schmacke NA; Karakoc B; Dulovic A; Junker D; Becker M; Rothbauer U; Osterman A; Spaeth PM; Ruhle A; Gapp M; Schneider S; Muenchhoff M; Hellmuth JC; Scherer C; Mayerle J; Reincke M; Behr J; Kääb S; Zwissler B; von Bergwelt-Baildon M; Eberle J; Kaderali L; Schneiderhan-Marra N; Hornung V; Keppler OT Cell Rep; 2021 Dec; 37(13):110169. PubMed ID: 34932974 [TBL] [Abstract][Full Text] [Related]
22. Immune response dynamics in COVID-19 patients to SARS-CoV-2 and other human coronaviruses. Ravindran R; McReynolds C; Yang J; Hammock BD; Ikram A; Ali A; Bashir A; Zohra T; Chang WLW; Hartigan-O'Connor DJ; Rashidi HH; Khan IH PLoS One; 2021; 16(7):e0254367. PubMed ID: 34242356 [TBL] [Abstract][Full Text] [Related]
23. Cross-Reactive Antibodies to SARS-CoV-2 and MERS-CoV in Pre-COVID-19 Blood Samples from Sierra Leoneans. Borrega R; Nelson DKS; Koval AP; Bond NG; Heinrich ML; Rowland MM; Lathigra R; Bush DJ; Aimukanova I; Phinney WN; Koval SA; Hoffmann AR; Smither AR; Bell-Kareem AR; Melnik LI; Genemaras KJ; Chao K; Snarski P; Melton AB; Harrell JE; Smira AA; Elliott DH; Rouelle JA; Sabino-Santos G; Drouin AC; Momoh M; Sandi JD; Goba A; Samuels RJ; Kanneh L; Gbakie M; Branco ZL; Shaffer JG; Schieffelin JS; Robinson JE; Fusco DN; Sabeti PC; Andersen KG; Grant DS; Boisen ML; Branco LM; Garry RF Viruses; 2021 Nov; 13(11):. PubMed ID: 34835131 [TBL] [Abstract][Full Text] [Related]
24. Seroprevalence and SARS-CoV-2 cross-reactivity of endemic coronavirus OC43 and 229E antibodies in Finnish children and adults. Tamminen K; Salminen M; Blazevic V Clin Immunol; 2021 Aug; 229():108782. PubMed ID: 34118402 [TBL] [Abstract][Full Text] [Related]
25. Healthy donor T cell responses to common cold coronaviruses and SARS-CoV-2. Woldemeskel BA; Kwaa AK; Garliss CC; Laeyendecker O; Ray SC; Blankson JN J Clin Invest; 2020 Dec; 130(12):6631-6638. PubMed ID: 32966269 [TBL] [Abstract][Full Text] [Related]
26. Serological responses in patients with severe acute respiratory syndrome coronavirus infection and cross-reactivity with human coronaviruses 229E, OC43, and NL63. Chan KH; Cheng VC; Woo PC; Lau SK; Poon LL; Guan Y; Seto WH; Yuen KY; Peiris JS Clin Diagn Lab Immunol; 2005 Nov; 12(11):1317-21. PubMed ID: 16275947 [TBL] [Abstract][Full Text] [Related]
27. Identification of SARS-CoV-2 Nucleocapsid and Spike T-Cell Epitopes for Assessing T-Cell Immunity. Lee E; Sandgren K; Duette G; Stylianou VV; Khanna R; Eden JS; Blyth E; Gottlieb D; Cunningham AL; Palmer S J Virol; 2021 Feb; 95(6):. PubMed ID: 33443088 [TBL] [Abstract][Full Text] [Related]
28. Seasonal coronavirus-specific B cells with limited SARS-CoV-2 cross-reactivity dominate the IgG response in severe COVID-19. Aguilar-Bretones M; Westerhuis BM; Raadsen MP; de Bruin E; Chandler FD; Okba NM; Haagmans BL; Langerak T; Endeman H; van den Akker JP; Gommers DA; van Gorp EC; GeurtsvanKessel CH; de Vries RD; Fouchier RA; Rockx BH; Koopmans MP; van Nierop GP J Clin Invest; 2021 Nov; 131(21):. PubMed ID: 34499051 [TBL] [Abstract][Full Text] [Related]
29. SARS-CoV-2 Infection Severity Is Linked to Superior Humoral Immunity against the Spike. Guthmiller JJ; Stovicek O; Wang J; Changrob S; Li L; Halfmann P; Zheng NY; Utset H; Stamper CT; Dugan HL; Miller WD; Huang M; Dai YN; Nelson CA; Hall PD; Jansen M; Shanmugarajah K; Donington JS; Krammer F; Fremont DH; Joachimiak A; Kawaoka Y; Tesic V; Madariaga ML; Wilson PC mBio; 2021 Jan; 12(1):. PubMed ID: 33468695 [TBL] [Abstract][Full Text] [Related]
30. Production of specific antibodies against SARS-coronavirus nucleocapsid protein without cross reactivity with human coronaviruses 229E and OC43. Lee HK; Lee BH; Seok SH; Baek MW; Lee HY; Kim DJ; Na YR; Noh KJ; Park SH; Kumar DN; Kariwa H; Nakauchi M; Heo SJ; Park JH J Vet Sci; 2010 Jun; 11(2):165-7. PubMed ID: 20458159 [TBL] [Abstract][Full Text] [Related]
31. The durability of immunity against reinfection by SARS-CoV-2: a comparative evolutionary study. Townsend JP; Hassler HB; Wang Z; Miura S; Singh J; Kumar S; Ruddle NH; Galvani AP; Dornburg A Lancet Microbe; 2021 Dec; 2(12):e666-e675. PubMed ID: 34632431 [TBL] [Abstract][Full Text] [Related]
32. Analysis of SARS-CoV-2 antibodies in COVID-19 convalescent blood using a coronavirus antigen microarray. de Assis RR; Jain A; Nakajima R; Jasinskas A; Felgner J; Obiero JM; Norris PJ; Stone M; Simmons G; Bagri A; Irsch J; Schreiber M; Buser A; Holbro A; Battegay M; Hosimer P; Noesen C; Adenaiye O; Tai S; Hong F; Milton DK; Davies DH; Contestable P; Corash LM; Busch MP; Felgner PL; Khan S Nat Commun; 2021 Jan; 12(1):6. PubMed ID: 33397903 [TBL] [Abstract][Full Text] [Related]
33. Antibodies specific to SARS-CoV-2 proteins N, S and E in COVID-19 patients in the normal population and in historical samples. Szymczak A; Jędruchniewicz N; Torelli A; Kaczmarzyk-Radka A; Coluccio R; Kłak M; Konieczny A; Ferenc S; Witkiewicz W; Montomoli E; Miernikiewicz P; Bąchor R; Dąbrowska K J Gen Virol; 2021 Nov; 102(11):. PubMed ID: 34816794 [TBL] [Abstract][Full Text] [Related]
34. The Potential of Developing Pan-Coronaviral Antibodies to Spike Peptides in Convalescent COVID-19 Patients. Rabets A; Bila G; Grytsko R; Samborskyy M; Rebets Y; Vari SG; Pagneux Q; Barras A; Boukherroub R; Szunerits S; Bilyy R Arch Immunol Ther Exp (Warsz); 2021 Mar; 69(1):5. PubMed ID: 33677719 [TBL] [Abstract][Full Text] [Related]
35. Longitudinal Profiling of Antibody Response in Patients With COVID-19 in a Tertiary Care Hospital in Beijing, China. Feng X; Yin J; Zhang J; Hu Y; Ouyang Y; Qiao S; Zhao H; Zhang T; Li X; Zhang L; Zhang J; Jin R; Feng Y; Su B Front Immunol; 2021; 12():614436. PubMed ID: 33790892 [TBL] [Abstract][Full Text] [Related]
36. Quantitative SARS-CoV-2 Serology in Children With Multisystem Inflammatory Syndrome (MIS-C). Rostad CA; Chahroudi A; Mantus G; Lapp SA; Teherani M; Macoy L; Tarquinio KM; Basu RK; Kao C; Linam WM; Zimmerman MG; Shi PY; Menachery VD; Oster ME; Edupuganti S; Anderson EJ; Suthar MS; Wrammert J; Jaggi P Pediatrics; 2020 Dec; 146(6):. PubMed ID: 32879033 [TBL] [Abstract][Full Text] [Related]
37. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting. Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J Front Immunol; 2021; 12():802858. PubMed ID: 35003131 [TBL] [Abstract][Full Text] [Related]
38. Targeting intra-viral conserved nucleocapsid (N) proteins as novel vaccines against SARS-CoVs. Thura M; Sng JXE; Ang KH; Li J; Gupta A; Hong JM; Hong CW; Zeng Q Biosci Rep; 2021 Sep; 41(9):. PubMed ID: 34519332 [TBL] [Abstract][Full Text] [Related]
39. Pre-pandemic antibodies screening against SARS-CoV-2 and virus detection among children diagnosed with eruptive fevers. Najimi N; Tajount L; Regragui Z; Remz C; Ait-Lhaj-Mhand R; Kadi C; Belayachi L; Seghrouchni F; Nadia Dakka ; El Hassani RA; Elharti E; Oumzil H; Bakri Y Int J Immunopathol Pharmacol; 2024; 38():3946320241260633. PubMed ID: 38836458 [TBL] [Abstract][Full Text] [Related]